Rituximab

“All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone)...” NCT05874778 ↗

“A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide,...” NCT00384111 ↗

“Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗

“This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients...” NCT04546620 ↗

“The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗

“All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m²,...” NCT03399513 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗

“Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗

“rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab...” NCT00581854 ↗

“Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗

“zanubrutinib combined with Pola-R-CHP regimen: zanubrutinib 160mg bid d1-d21/C1-C6; polatuzumab 1.8mg/kg d1/C1-C6; rituximab 375mg/㎡, iv, d1/C1-C6; cyclophosphamide 750mg/㎡,...” NCT07371923 ↗

“This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas,...” NCT02678299 ↗

“A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a...” NCT01950273 ↗

“standard doses of R-CHOP21 chemotherapy (375 mg/m(2) intravenous rituximab, 750 mg/m(2) intravenous cyclophosphamide, 50 mg/m(2) intravenous doxorubicin, and 1·4 mg/m(2)...” PMID 24831981 ↗ May 2014

“At present, the only treatment option is Rituximab (an anti-cluster of differentiation antigen 20 (CD20) monoclonal antibody), which effectuates a limited but clinically...” NCT05939037 ↗

“Eligible patients received intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum 2 mg/m2), and oral prednisone...” PMID 34022150 ↗ May 2021

“A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With...” NCT04049825 ↗

“Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a...” NCT04915482 ↗

“Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of...” NCT01019863 ↗

“PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to...” NCT03022123 ↗

“OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at...” NCT01673295 ↗

“The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide,...” NCT00901615 ↗

“Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in...” NCT01389427 ↗

“short-course chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended...” PMID 18981007 ↗ Nov 2008

“Study on the Treatment of Double/Triple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin,...” NCT07552324 ↗

“Treatment with [90Y]-ibritumomab tiuxetan is preceded by an infusion of rituximab (Rituxan, Mabthera) in order to optimize the biodistribution of radiolabeled antibody by...” NCT00850512 ↗

“Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500...” NCT00392990 ↗

“R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗

“Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the...” PMID 33394214 ↗ Jan 2021

“Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine,...” NCT00554164 ↗

“GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor...” PMID 28637670 ↗ Jun 2017

“By sequentially combining Rituximab and Abatacept, we thus aim to enhance the tolerogenic potential of these drugs and seek to eliminate autoantibody production and...” NCT04120831 ↗

“with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗

“Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite...” NCT04692493 ↗

“All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5),...” NCT00521560 ↗

“Day 1 of each cycle will consist of an infusion of rituximab followed by the initiation of a 96-hour continuous infusion of etoposide, doxorubicin, and vincristine and oral prednisone.” NCT00799136 ↗

“Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.” NCT05050630 ↗

“Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00005780 ↗

“Participants who experience life-threatening toxicities caused by uncontrollable proliferation of fhB7H3.CAR-Ts will receive infusion of Rituximab (Rituxan or Ruxience or Halpryza)” NCT05211557 ↗

“ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗

“Patients received 375 mg/m(2) rituximab, 400 mg/m(2) cyclophosphamide, 25 mg/m(2) doxorubicin, and 1 mg vincristine on day 1 of each cycle, and 40 mg/m(2) prednisone on days 1-5.” PMID 21482186 ↗ Apr 2011

“This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.” NCT04842318 ↗

“Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.” NCT00003659 ↗

“Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.” NCT05189197 ↗

“Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)” NCT03964090 ↗

“R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle” NCT05518383 ↗

“Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5.” NCT01278602 ↗

“Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.” NCT04023916 ↗

“Rituximab, an anti-CD20 monoclonal antibody, and prednisone, a glucocorticoid, further enhance anti-lymphoma activity and are established components of immunochemotherapy.” NCT07159906 ↗

“Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice.” NCT03003520 ↗

“azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 cisplatin 70 mg/m2 I.V. D8” NCT03719989 ↗

“This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab” NCT07464210 ↗

“Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.” NCT01135641 ↗

“Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, bid D1-21” NCT06005870 ↗

“Rituximab 375mg/ m2 IV day 1 Cyclophosphamide 750mg/ m2 IV day 1 Adriamycin 50mg/ m2 IV day 1 Vincristine 1.4mg/ m2 (max 2mg) IV day 1 Prednisone 100mg po days 1-5” NCT00530179 ↗

“we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL” PMID 38113470 ↗ Jan 2024

“Intravenous administration: Rituximab 375 mg/m2, Cyclophosphamide 400 mg/m2, Doxorubicin 25 mg/m2, Vincristine 1 mg, and Oral administration: Prednisone 40 mg/m2” NCT07215585 ↗

“sequential intravenous administration of Rituximab, Cyclophosphamide (specifically dose-adjusted for end-stage renal disease), and rabbit Thymoglobulin (rATG)” NCT07607197 ↗

“Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab.” PMID 19843887 ↗ Oct 2009

“This phase 1b study evaluated safety and efficacy of acalabrutinib, venetoclax, and rituximab (AVR) in treatment-naive mantle cell lymphoma (TN MCL).” PMID 38781315 ↗ Sep 2024

“Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5” NCT06925555 ↗

“The desensitization regimen consisted of 2 doses of IVIG (2  g/kg), a single dose of rituximab (375  mg/m), and 4 doses of bortezomib (1.3  mg/m).” PMID 26844479 ↗ Feb 2016

“Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD).” NCT00145587 ↗

“Dose Adjusted - Etoposide Prednisone Vincristine Cyclophosphamide Doxorubicin - Rituximab (DA-EPOCH-R) and nivolumab are both feasible treatments.” NCT03620578 ↗

“In this research study, the investigators are adding the drug rituximab (Rituxan) to the drug cytarabine for the stem cell mobilization process.” NCT01182415 ↗

“Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO)” PMID 39550172 ↗ Nov 2024

“Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab” NCT01046825 ↗

“1 bag containing 1000 mg of rituximab* in 500 ml of NaCl 0.9% * Mabthera® and all registered biosimilars are likely to be used in this trial” NCT05211401 ↗

“Rituximab: 375 mg/m2, endovenous, according to the protocol of the service, day 1 (except in the first cycle, in which it will be on day 5).” NCT01066429 ↗

“Nivolumab 40 mg (Day 2), Rituximab 375 mg/m2 (Day 1) and Prednisolone 60 mg/m2 (Days 1-5) are administered at constant unchangeable doses.” NCT06871007 ↗

“polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1” NCT05253495 ↗

“R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks” NCT00391066 ↗

“R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks” NCT00801060 ↗

“A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles” NCT02390869 ↗

“3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy” NCT03399747 ↗

“Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells.” NCT03307746 ↗

“R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection.” NCT06601504 ↗

“Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen.” NCT06334991 ↗

“either Rituximab 375mg/m², intravenous infusion, Day 1 of each cycle, C1-C6; or Obinutuzumab 1000mg, intravenous infusion” NCT07355699 ↗

“During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8” NCT01157988 ↗

“At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8.” NCT00089284 ↗

“Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle” NCT00268853 ↗

“Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation” NCT01136395 ↗

“R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.” NCT04661007 ↗

“Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,” NCT00774826 ↗

“rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2” NCT00864942 ↗

“D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.” NCT03931642 ↗

“3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.” NCT02340936 ↗

“Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone” NCT07608978 ↗

“First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)” NCT06454266 ↗

“Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day” NCT02842931 ↗

“Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin” NCT06743945 ↗

“80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks” NCT00286780 ↗

“* tocilizumab * rituximab * HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes” NCT04000698 ↗

“Two kinds of anti-CD 20 monoclonal antibody could be used in this study, including Rituximab and Ortuzumab.” NCT05718856 ↗

“Doses of iv rituximab (1 g) were given on d 1 and 15, after pretreatment with 125 mg iv methylprednisolone.” PMID 22767640 ↗ Jul 2012

“dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R)” PMID 32453640 ↗ May 2020

“Efficacy and Safety of Rituximab in Reducing Relapses in Children With Steroid-Sensitive Nephrotic Syndrome” NCT07049172 ↗

“Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.” NCT03286556 ↗

“Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte” NCT01458730 ↗

“Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.” NCT04935177 ↗

“Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8.” NCT01208896 ↗

“The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD.” NCT00143559 ↗

“Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.” NCT01638715 ↗

“Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine” NCT00875667 ↗

“Patients with active RA were randomly assigned to rituximab (1,000 mg on days 1 and 15) or placebo.” PMID 18512710 ↗ Jun 2008

“Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗

“treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)” NCT00466258 ↗

“Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B” NCT01184885 ↗

“Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.” NCT00251394 ↗

“Drug: Rituximab Rituximab will be given at a dose of 375 mg/m2 by IV on day 1 in a 21-day cycle” NCT06890585 ↗

“Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases” NCT07051070 ↗

“Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses” NCT00774202 ↗

“Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine” PMID 26282634 ↗ Aug 2015

“Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816 ↗

“Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.” NCT01527422 ↗

“Acalabrutinib, lenalidomide, rituximab will be given as described in the "Arms" decriptions.” NCT04094142 ↗

“R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))” NCT02054559 ↗

“Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim” NCT02142049 ↗

“Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9)” NCT00322218 ↗

“Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD.” NCT00145613 ↗

“SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)” NCT06104553 ↗

“Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells.” NCT06829771 ↗

“Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)” NCT06891157 ↗

“Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma” NCT05299164 ↗

“either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]” NCT04628494 ↗

“Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab.” NCT06594432 ↗

“either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]” NCT07226752 ↗

“The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.” NCT05234684 ↗

“some patients will respond to treatment with the chimeric anti-CD 20 antibody Rituximab” NCT01134432 ↗

“CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.” NCT06463691 ↗

“In the R-CHOP50 group, patients were given rituximab 375 mg/m2 intravenously on day 0” PMID 31126528 ↗ Jun 2019

“patients received 375 mg/m2 of Rituximab once every 4 weeks by intravenous injection” NCT07505849 ↗

“Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion” NCT04268771 ↗

“Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide.” NCT00765245 ↗

“Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle” NCT00868413 ↗

“Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT” NCT06646497 ↗

“Lymphoma Protocol consisting of four weekly doses of 375 mg/m2 of rituximab (RTX)” NCT06680349 ↗

“Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab” NCT04844866 ↗

“NB02 (Poseltinib) combined with Rituximab and lenalidomide as a Salvage Therapy” NCT06737250 ↗

“R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone)” NCT00582725 ↗

“Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)” NCT05051891 ↗

“Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6” NCT04332822 ↗

“Rituximab is designed to attach to cancer cells, which may cause them to die.” NCT01983761 ↗

“R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone)” NCT02858258 ↗

“rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone” NCT03293173 ↗

“Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.” NCT04578613 ↗

“* rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.” NCT04010968 ↗

“Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days” NCT05014100 ↗

“antibody administration (Siplizumab (or ATGAM), rituximab and tegoprubart)” NCT06972069 ↗

“Patients obtain the standard of care: combination rituximab and venetoclax” NCT05069051 ↗

“R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)” NCT03023878 ↗

“fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)” NCT03836261 ↗

“Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7” NCT06778902 ↗

“Rituximab (Mabthera/Rituxan®) will be administered as per local practice” NCT04833114 ↗

“Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle” NCT07072208 ↗

“Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:” NCT06674096 ↗

“Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid” NCT00525616 ↗

“rituximab, 375 mg per square meter of body-surface area days -7 and -2” NCT00063817 ↗

“R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）” NCT03980002 ↗

“rituximab (R, 375 mg/m²) is given as an intravenous infusion on day 0” NCT07604987 ↗

“Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone” NCT06549595 ↗

“AlloNK, dosed after a conditioning regimen, combined with Rituximab.” NCT06991114 ↗

“cyclophosphamide. doxorubicin, vincristine , prednisone + Rituximab” NCT04243434 ↗

“rituximab, Two infusions separated by 2 weeks, Intravenous infusion” NCT01682512 ↗

“R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide.” NCT03450343 ↗

“combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle” NCT02700022 ↗

“Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w” NCT00991211 ↗

“Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone” NCT02890602 ↗

“Rituximab was provided prior to transplant for PTLPD prophylaxis.” NCT00186823 ↗

“Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone” NCT03995147 ↗

“either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab)” NCT01526057 ↗

“Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06517511 ↗

“Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06647940 ↗

“Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT07398638 ↗

“Rituximab 375 mg/m2 was administered intravenously every 28 days” PMID 35796785 ↗ Jul 2022

“Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone” NCT01843868 ↗

“Rituximab is a chimeric human/murine IgG1 monoclonal antibody.” NCT00859001 ↗

“drug Nivolumab before and in combination with drug Rituximab” NCT03245021 ↗

“Rituximab: 375 mg/m2, intravenous drip, Day 1 of each cycle” NCT07499271 ↗

“rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1” NCT01502982 ↗

“Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1°” NCT00795613 ↗

“Rituximab by intravenous infusion over 6-8 hours on day 1” NCT00836173 ↗

“The antibody rituximab is given on the day of admission.” NCT01702961 ↗

“Rituximab in combination with idelalisib or bendamustine” NCT02970318 ↗

“another medication called rituximab may be used instead” NCT01275287 ↗

“rituximab (given intravenously at a dose of 500mg once)” NCT02834468 ↗

“Rituximab: 375 mg/m2 given intravenously (IV) on day 0” NCT04992377 ↗

“Rituximab 375 mg/m2 IV is given on Day 1 of each cycle” NCT07409428 ↗

“the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1)” NCT03129828 ↗

“Rituximab intravenous infusion dosage 375 mg/m² day 1” NCT01457144 ↗

“Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0” NCT03715309 ↗

“Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle.” NCT05933967 ↗

“Rituximab-ifosfamide, carboplatin, etoposide (R-ICE)” NCT03391466 ↗

“Rituximab 375 mg/m\^2 IVPB with premedications Day 1” NCT02633137 ↗

“Rituximab：375 mg/m2/ time, once a week for 4 times;” NCT05969522 ↗

“Rituximab with 12 x 2 Gy involved site radiotherapy” NCT05045664 ↗

“rituximab + dexamethasone + cytarabine + cisplatin” NCT02055924 ↗

“rituximab and/or dexamethasone and/or vincristine” NCT03236857 ↗

“Rituximab: 375 mg/m², intravenous infusion, Day 1” NCT07680933 ↗

“Rituximab 375mg/m2 i.v. on day 1 of every cycle.” NCT07570017 ↗

“Rituximab 375mg/m2 IV weekly x 4, start day -7” NCT01181258 ↗

“rituximab 375 mg/m2 IV Weekly x 4 1 cycle only” NCT00166439 ↗

“of rituximab (RTX) (Mabthera®) is non-inferior” NCT05116228 ↗

“Rituximab 375 mg/m²,intravenous ( iv ), day 0” NCT00946374 ↗

“rituximab (IV, 250 mg/m2 on days -21 and -14)” NCT00336843 ↗

“Rituximab: 375 mg/m2, IV, day 1 of each cycle” NCT03650933 ↗

“Rituximab 375mg/m² IV day 1 per 21-day cycle” NCT07538180 ↗

“Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1)” NCT04066920 ↗

“375 mg/m2 intravenous on day 1 for rituximab” PMID 37011643 ↗ Mar 2023

“rituximab: 375 mg/m2 intravenously on day 7” NCT06445257 ↗

“Rituximab IV if LNH type B (375 mg/m²) day1” NCT00863460 ↗

“the anti-CD20 monoclonal antibody rituximab” NCT02012088 ↗

“steroids, IVIG, azathioprine, and rituximab” NCT03412188 ↗

“Methotrexate or leflunomide + rituximab or” NCT02714634 ↗

“Rituximab 375 mg/m2 IV Day 1, Cycles 1-6;” NCT02747732 ↗

“combined with rituximab 375mg/m2 IV day 0” NCT00854568 ↗

“Mabthera -Rituximab (375 mg/sm, D1)/cycle” NCT00842114 ↗

“Rituximab, 250 mg/m2 on days -21 and -14.” NCT00644371 ↗

“Rituximab (Innovent) 375 mg/m², iv Day 1” NCT07494565 ↗

“Rituximab,375mg／㎡, d1,intravenous drip” NCT06412068 ↗

“Rituximab vs DPP/DCEP-G vs observation” NCT03695055 ↗

“treatment rituximab 375 mg/m2,ivgtt D0” NCT03373019 ↗

“Day +90: rituximab (375mg/m2 IV once)” NCT03128996 ↗

“Rituximab (375 mg/m²) pre-operatively” NCT07519005 ↗

“RITUXIMAB Dosage: 375mg/m2, IV, day 1” NCT01361191 ↗

“Rituximab(B-NHL) 375 mg/m2/day IV d0” NCT01818908 ↗

“Venetoclax and rituximab association” NCT03455517 ↗

“Drug: RiTUXimab Injection [Rituxan]” NCT04542629 ↗

“Rituximab 375 mg/m2 IV on D0 or D1” NCT05966233 ↗

“Rituximab 375 mg/sqm iv day 0 or 1” NCT01805557 ↗

“* Rituximab 375 mg/m2, e.v. day 1” NCT02371161 ↗

“Rituximab Gemcitabine Oxaliplatin” NCT01670370 ↗

“Rituximab 375 mg/m²/d i.v. (d0,5)” NCT02531841 ↗

“EU-sourced rituximab (Mabthera®)” NCT04671420 ↗

“Rituximab (375mg/m\^2) on day 1;” NCT06244368 ↗

“* Rituximab i.v.: 375 mg/m2 (D0)” NCT05820841 ↗

“Rituximab: 375mg/m2 iv.drip D1;” NCT05577364 ↗

“CHOP-14- Rituximab x 8 courses” NCT00561379 ↗

“Rituximab at 375mg/m2 on day 1” NCT06290817 ↗

“Rituximab 375 mg/m² i.v. d0,14” NCT06830421 ↗

“(rituximab 375mg/m2 d0 ivgtt)” NCT03513601 ↗

“R-CHOP: Rituximab 375mg/m2 d0” NCT05164770 ↗

“Rituximab 375mg//m2, ivgtt,d1” NCT03201471 ↗

“Rituximab: 375 mg/m² day 1 iv” NCT02063685 ↗

“Rituximab (R) 375mg/m2 IV d0” NCT06158399 ↗

“Rituximab 375 mg/m2 D1, I.V.” NCT06255704 ↗

“rituximab 375 mg/m2 on day 1” NCT03392714 ↗

“R-CHOP：Rituximab 375mg/m2 d0” NCT05097443 ↗

“Rituximab 375 mg/m2 IV 0 day” NCT03479918 ↗

“* Rituximab 375 mg / m\^2，D1” NCT05257018 ↗

“Rituximab: 375 mg/m2 IV day0” NCT04432402 ↗

“rituximab 375 mg/m2,ivgtt D1” NCT03318835 ↗

“rituximab 375 mg/m2,ivgtt D1” NCT04164368 ↗

“rituximab infusion [Rituxan]” NCT05025423 ↗

“Rituximab 375 mg/m2 D1, I.V.” NCT04736914 ↗

“Rituximab: 375 mg/m2, IV, d1” NCT07059650 ↗

“* Rituximab 375mg/m2, IV, D1” NCT05245656 ↗

“Rituximab 375mg/m2, ivd, D1” NCT05093140 ↗

“Rituximab: 375 mg/m², Day 0” NCT07677813 ↗

“rituximab 375mg/m2 IV day 0” NCT01914718 ↗

“Rituximab：375mg/m2，ivgtt，D0” NCT02526823 ↗

“Rituximab：375mg/m2，ivgtt，D0” NCT04152577 ↗

“Rituximab intravenous drip” NCT06760039 ↗

“rituximab 500 mg/m2 day -1” NCT01582048 ↗

“rituximab 375mg/m2, iv d1” NCT06062641 ↗

“Drug: Rituximab Rituximab” NCT06486337 ↗

“Rituximab 375 mg/m2 d0 iv” NCT05347641 ↗

“Rituximab (375 mg/m2，d0)” NCT06569485 ↗

“* Rituximab * Cytarabine” NCT00801580 ↗

“rituximab 375mg/m2 day 0” NCT01804127 ↗

“Rituximab: 375 mg/m2, d0” NCT05974085 ↗

“rituximab: 375 mg/m2, D0” NCT06901999 ↗

“Rituximab-375 mg/m2 : D1” NCT01285765 ↗

“Rituximab 375mg/m2 IV D0” NCT05348213 ↗

“rituximab or biosimilar” NCT05468320 ↗

“incorporating rituximab” NCT04684979 ↗

“Rituximab 375 mg/m² Q3W” NCT04980859 ↗

“Rituximab 375 mg/m2 D1” NCT06750991 ↗

“Rituximab 375 mg/m2 D1” NCT06701357 ↗

“Rituximab 375mg/m2, D0” NCT05040555 ↗

“Rituximab 375mg/m2，d0” NCT04134247 ↗

“Rituximab (MabThera):” NCT00568477 ↗

“MabThera (rituximab)” NCT02371096 ↗

“rituximab (Rituxan®)” NCT04047628 ↗

“Rituximab Injection” NCT04083014 ↗

“rituximab 375 mg/m²” NCT04263584 ↗

“Rituximab: 375mg/m2” NCT07122609 ↗

“Rituxan (rituximab)” NCT03535298 ↗

“Drug: Rituximab” NCT01253460 ↗

“Drug: Rituximab” NCT03777085 ↗

“dd 2, Rituximab” NCT01516593 ↗

“• Rituximab” NCT07124078 ↗

“• Rituximab” NCT06821542 ↗

“* Rituximab” NCT02171104 ↗

“Rituximab” NCT03161457 ↗

“Rituximab” NCT03571308 ↗

NCT00384553 ↗

NCT02525172 ↗

NCT04899453 ↗

NCT00039195 ↗

NCT01209130 ↗

NCT02624492 ↗

NCT00343447 ↗

NCT05457556 ↗

NCT05389423 ↗

NCT00344149 ↗

NCT00073957 ↗

NCT00274989 ↗

NCT00462345 ↗

NCT01319981 ↗

NCT01086540 ↗

NCT01491841 ↗

NCT00210340 ↗

NCT02733042 ↗

NCT00210353 ↗

NCT03571321 ↗

NCT00210379 ↗

NCT01810926 ↗

NCT00092222 ↗

NCT01611259 ↗

NCT03943901 ↗

NCT06441097 ↗

NCT01611090 ↗

NCT01234467 ↗

NCT01086631 ↗

NCT01842386 ↗

NCT00720876 ↗

NCT00275054 ↗

NCT01992653 ↗

NCT07015242 ↗

NCT06756308 ↗

NCT00980395 ↗

NCT00003554 ↗

NCT01695941 ↗

NCT07247383 ↗

NCT02623920 ↗

NCT06541665 ↗

NCT05179733 ↗

NCT01810588 ↗

NCT07550855 ↗

NCT02734771 ↗

NCT06410833 ↗

NCT05388123 ↗

NCT06611696 ↗

NCT04231448 ↗

NCT00691652 ↗

NCT03003546 ↗

NCT00980304 ↗

NCT00003595 ↗

NCT04083066 ↗

NCT05868837 ↗

NCT00651755 ↗

NCT02203526 ↗

NCT01886872 ↗

NCT01013961 ↗

NCT04231877 ↗

NCT03569995 ↗

NCT01400685 ↗

NCT03003039 ↗

NCT03805932 ↗

NCT00907751 ↗

NCT00003605 ↗

NCT00274924 ↗

NCT03571568 ↗

NCT01813227 ↗

NCT00275613 ↗

NCT03002038 ↗

NCT00849355 ↗

NCT05868395 ↗

NCT00074282 ↗

NCT00424502 ↗

NCT01277172 ↗

NCT01180036 ↗

NCT00525876 ↗

NCT02735876 ↗

NCT04994626 ↗

NCT00072592 ↗

NCT00072514 ↗

NCT06929624 ↗

NCT01811368 ↗

NCT00074438 ↗

NCT01453205 ↗

NCT05287984 ↗

NCT01087151 ↗

NCT02731560 ↗

NCT02624986 ↗